In our study, although OS, RFS and BCSS were all evaluated, RFS and BCSS would be more appropriate endpoints for evaluating the importance of HER4 on predicting patient prognosis than OS because both RFS and BCSS have more emphasis on breast cancer-related outcomes. The gene discussed is ERBB4; the disease is breast carcinoma.